Close
Almac
Achema middle east

SG Austria gets milestone payment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...
- Advertisement -

The Economic Development Board of Singapore has paid milestone payment to SG Austria, an affiliate of Nuvilex.The milestone was paid for achieving key scientific milestones following independent scientific review of the company’s ongoing R&D projects. The payment is part of the previously announced five-year, $1.5m grant funded by the Economic Development Board of Singapore in 2008 and covers four of the company’s ongoing projects.Nuvilex president and CEO Robert Ryan said they can look forward to some of the data being released to the scientific and investor communities in the near future.

“We are also pleased to note that other, separate grant and milestone payments are on track over the next 12 months, increasing the value of our energies in Nuvilex, and in particular our affiliate SG Austria, the live-cell encapsulation platform, and the promises it holds for the scientific and medical fields,” Ryan said.

Latest stories

Related stories

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Novartis to Lower Innovative Medicines Price in the US

Novartis, which is a leading global innovative medicines company,...

New Agreements with Pharmaceuticals Target Lower U.S. Drug Prices

President Donald Trump on December 19, 2025, said that...

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »